

Advancements in the Recognition and Diagnosis of Traumatic Brain Injury



Mild Traumatic Brain Injury: It's in the Blood

Deborah B. Diercks, MD, MSc Professor and Chair, Department of Emergency Medicine University of Texas Southwestern Medical Center

Learning Objectives

After participation in this educational activity, participants will be able to

Identify patients to utilize biomarker testing in the diagnosis of mild to moderate Traumatic Brain Injury Determine patients that need head CT scans and those that may be diagnosed without head CT











Reference standard for di	agnosis is problematic		
	Disease	No Disease	
Index Test+	TP	FP	
Index Test-	FN		
Acute symptoms neither s	ensitive nor specific for concus	sion	
False +	Fa	lse -	
Syncope	Pu	rposeful under-reporting	
Seizure	De	mentia	
Acute stress disorder	Dr	ug use	
Migraine HA			
Cervical injury			
Druguse			

Current ED Clinical Evaluation of Patients with Suspected Mild TBI

• Head CT Scan most everyone

- Selective head CT scanning
 - Clinician gestalt
 - Clinical guidelines (ACEP, Scandinavian Guidelines)
 Clinical decision rules

Goal: Reduce CT use without affecting patient outcomes

Clinical Decision Rules - CCTH Rule (2001)

- 3121 enrolled (only 67% scanned)
- 98.4% sensitive (96% 99%) for "clinically important" brain injury
- 92.0% (88% 94%) for any injury on CT
- For "clinically unimportant injury" the rule identified 70/94
 Sensitivity 74.5% (64.4% 82.9%)
- CT scans now higher resolution
- What about those not scanned?



Canadian CT Head Rule

Instructions

- Only apply to:
- Glasgow Coma Scale (GCS) 13–15 with LOCAmnesia to the head injury event
- Confusion
- Exclusion Criteria:
- Age <16
- Blood thinners
- Seizure after injury



CCTH Rule Interpretation

High Risk Criteria

- GCS <15 (2 hrs post-injury)
 Suspected open or depressed skull fracture
- · Signs of basilar skull fracture
- ≥2 episodes of vomiting
 Age ≥65 years

Medium Risk Criteria • Retrograde amnesia ≥ 30 minutes

- "Dangerous" mechanism
 _ Pedestrian struck by motor vehicle
 - Occupant ejected from motor vehicle
 - Fall from >3 feet or >5 stairs)

Canada - 1822 patients with GCS score of 15

Canadian Head CT rule

- Neurosurgical 100% sensitiveClinically important injury
 - Sensitivity 100%
 - Specificity 50.6%
- New Orleans Head CT rule

 Neurosurgical -100% sensitive
- Clinically important injury
 - Sensitivity 100%
 - Specificity 12.7%



U.S. (314 Patients with GCS 15)

Canadian Head CT rule

- Neurosurgical 100% sensitiveClinically important injury
 - Sensitivity 100%
 - Specificity 36.3%
- New Orleans Head CT rule

 Neurosurgical -100% sensitive
- Neurosurgical -100% sensitive
 Clinically important injury

 Sensitivity 100%
 Specificity 10.2%

Netherlands - 3181 patients with a GCS score 13 to 15

Canadian Head CT rule

Neurosurgical – 100% sensitive
 Clinically important injury

 Sensitivity 83.4%–87.2%

- Specificity 37.2%-39.7%

New Orleans Head CT rule

- Neurosurgical -100% sensitive
 Olisieally important injury
- Clinically important injury
 - Sensitivity 97.7%–99.4%
 Specificity 3.0%–5.6%
- ve



Difficulty Implementing CCTHR

- Intervention and control sites had and INCREASE in imaging (13.3% and 6.7%)
- Increase 6.7% MORE in intervention sites (p=0.16)
- + 5.3% (95% Cl 2.5% to 8.1%) reduction in CT use for given time points (3.8% average reduction pre- and post-intervention periods)









Study Design

- Non-penetrating head injury
- 18 years or greater with GCS 9 to 15 (n=1959)
- Subset GCS 14 to 15 (n= 1920)
- CT done as standard of care
- Blood sample obtained within 12 hours of injury

DUIDU LA ELIDA DI (C

- Pre-specified cutoffs (positive if either or both above)
 UCH-L1 327 pg/mL
 - GFAP 22 pg/mL



All Subject	s, GCS 9-15 (n	=1959)	Mild	TBI Subjects,	GCS 14-15 (n=	:1920)
	CT+	CT-			CT+	CT-
lest+	122	116	6 Test+		110	1144
īest-	3	668	3 Test-		3	663
Subjects	Sensitivity	Specificity	PPV	NPV	LR+	LR-
GCS 9–15 n=1959)	0.976 (0.931–0.995)	0.364 (0.342–0.387)	0.095 (0.079–0.112)	0.996 (0.987–0.999)	1.5 (1.455–1.616)	0.07 (0.00–0.153)
GCS 14-15	0.973	0.367	0.088	0.995	1.5	0.07

7

Subjects w	/ GCS 13-15 (n	=1901)	Sul	bjects w GCS 15	(n=1798)		
	CT+	CT-			CT+	CT-	
Test+	115	1061	Tes	t+	90	999	
Test-		720	Tes	t-		696	
	Sensitivity %	Specificity %	PPV %	NPV %	LR+	LR-	
GCS 13-15 (n=1901)	95.8 (90.6, 98.2)	40.4 (38.2, 42.7)	9.8 (8.2, 11.6)	99.3 (98.4, 99.7)	1.61 (1.51, 1.69)	0.10 (0.04, 0.23)	
GCS 15 (n=1798)	95.7 (89.6, 98.3)	41.1 (38.7, 43.4)	8.3 (6.8, 9.8)	99.4 (98.5, 99.8)	1.63 (1.51, 1.71)	0.10 (0.04, 0.26)	

Table of CC	THR by CT		
		CT	
CCTHR	CT+	CT-	Total
Yes	47	379	426
No	20	473	493
Total	67	852	919
Table of As	say by CT		
		CT	
Assay	CT+	CT-	Total
Positive	64	521	585
Negative	3	331	334

15) THR sitivity: 70.1% (57.7%–80.7%) eificity: 55.5% (52.1%–58.9%) : 5.5% (93.8%–97.5%)

iomarker Assay ensitivity: 95.5% (87.5%–99.1%) pecificity: 38.8% (35.6%–42.2%) PV: 99.1% (97.4%–99.8%)

Evaluation of Glial and Neuronal Blood Biomarkers Compared with Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients with Mild Traumatic Brain Injury



	CCHR + GFAP	NOC + GFAP	
AUC	0.88	0.85	
95% CI	[0.81-0.95]	[0.77-0.94]	

	CCHR (n=346) (%)	NOC (n=344) (%)	NEXUS II (n=345) (%)
How comfortable would	you be in following this ru	le for this patient?	
Very comfortable	49 (14)	46 (13)	52 (15)
Comfortable	162 (47)	158 (46)	140 (41)
Neutral/Unsure	83 (24)	93 (27)	67 (19)
Uncomfortable	31 (9)	36 (11)	68 (20)
Very uncomfortable	21 (6)	11 (3)	18 (5)
	CCHR (n=338) (%)	NOC (n=324) (%)	NEXUS II (n=341) (%)
Do you use this rule on	a regular basis when evalu	ating MTBI patients for a h	lead CT?
I use this rule regularly	89 (26)	54 (16)	166 (49)



Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study

John X Yuu", Esher L Yuhi, Federick K Korley¹, Bhan A Wesker', Xaoying Sun'i, Ross C Puffer', Hansen Deng¹, Wanaard Doy', Jakuah Chandral, Sabrina R Taylor', Adam R Fergason', J Russel Hwi, Min Rabinowitz', Ana M Puscio¹, Palik Makherjer², Mary J Vissar', Kevin K W Wang', Ramon Diaz-Arastal, David O Gionkwef, Sonia Jain', Geoffrey T Mariny¹, TRACK-Bill Investidation

450 patients were CT negative:

- 120 MRI positive
- 330 MRI negative

Where Now – ACEP Clinical Policy mTBI 2023

- Level A recommendation "Use the Canadian CT Head Rule (CCHR) to provide decision support and improve head CT utilization in adults with a minor head injury."
- Level B recommendations "Use the National Emergency X-Radiography Utilization Study (NEXUS) Head CT decision tool (NEXUS Head CT) or the New Orleans Criteria (NOC)... however, the lower specificity of the NEXUS Head CT and NOC compared with CCHR may lead to more unnecessary testing"



ACEP

- Serum biomarkers such as S-100, or GFAP may add additional information.
- "However, at this point, strong data on biomarker use with or without other decision tools is lacking and limited by the availability of these tests".
- EEG-based algorithms (artificial intelligence) may offer improved diagnostic capabilities (future)



Clinical Adoption in ED

- Will providers order the test?
- Does testing impact ED operations & patient throughput?
- Are test results available in timely fashion (point-of-care whole blood)?
- Do patients accept the test (shared decision making)?
- · Is the test cost effective?
- What to do with biomarker + patients with normal head CT scan?
 Lack of expert mTBI clinics
- The "so what" factor
 - "Non-clinically important" CT findings
 - Nihilistic view of mTBI therapy in general







- Extensive collection of additional BioMarker content
 TBI,
 HS Troponin
 Sepsis
- More than 8 hours of content in short, independently accredited sessions
- 6 TBI videos
- 14 hs cTn videos
- 1 procalcitonin video
- No fee to obtain CME credit



Thank You for Attending